EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐Term Exposure to Non‐Steroidal Anti‐Inflammatory Medication in Relation to Dementia Risk

Ilse Vom Hofe iD, Bruno H Stricker, M Kamran Ikram, Frank J Wolters, M Arfan Ikram

Journal of the American Geriatrics Society · 2025-05 · 73 (5) · 1484-1490

DOI: 10.1111/jgs.19411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 04.03.2025. Verfasst von Ilse Vom Hofe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Dementia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Brain and Behavior Research Foundation, Research Institute for Diseases in the Elderly, Erasmus Medisch Centrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐steroidal anti‐inflammatory (NSAID) medication could reduce dementia risk due to anti‐inflammatory and possibly amyloid‐lowering properties. However, the results of observational studies and short‐term randomized‐controlled trials have been inconsistent, and duration and dose–response relationships are still unclear.

Methods

We included 11,745 dementia‐free participants from the prospective population‐based Rotterdam Study (59.5% female, mean age 66.2 years). NSAID use from 1991 was derived from pharmacy dispensing records, from which we determined cumulative duration and dose. We defined four mutually exclusive categories of cumulative use: non‐use, short‐term use (< 1 month), intermediate‐term use (between 1 and 24 months), and long‐term use (> 24 months). We determined the association with dementia risk until 2020 using Cox regression models, including NSAID use as a time‐varying exposure. Models were adjusted for lifestyle factors, comorbidity, and comedication use. We repeated the analyses stratified by previously established amyloid‐β lowering properties of different NSAIDs.

Results

During an average follow‐up period of 14.5 years, a total of 9520 (81.1%) participants had used NSAIDs at any given time, and 2091 participants developed dementia. Use of NSAIDs was associated with lower dementia risk for long‐term users (HR [95% CI]: 0.88 [0.84–0.91]), and a small increased risk with short‐term use (HR [95% CI]: 1.04 [1.02–1.07]) or intermediate‐term use (HR: 1.04 [1.02–1.06]). The cumulative dose of NSAIDs was not associated with decreased dementia risk (HR for ≤ 25th percentile: 1.06 [1.03–1.09], 26–50th percentile: 1.02 [0.99–1.05], 51–75th percentile: 1.03 [0.99–1.06], > 75th percentile: 0.99 [0.96–1.02]). Associations were somewhat stronger for long‐term use of NSAIDs without known effects on amyloid‐β than for amyloid‐lowering NSAIDs (HR [95% CI]: 0.79 [0.74–0.85] versus 0.89 [0.85;0.93]).

Conclusion

Long‐term NSAID use, but not cumulative dose, was associated with decreased dementia risk. This suggests that prolonged rather than intensive exposure to anti‐inflammatory medication may hold potential for dementia prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalDementiaHumansFemaleMaleAgedProspective StudiesNetherlandsRisk FactorsDose-Response Relationship, DrugMiddle AgedTime FactorsAged, 80 and over

Stichwörter der Autor:innen

dementianeuro‐inflammationnon‐steroidal anti‐inflammatory drugspopulation‐based

Substanzen

Anti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.

ORCID-Profile: Ilse Vom Hofe

Förderung

  • Brain and Behavior Research Foundation
  • Research Institute for Diseases in the Elderly
  • Erasmus Medisch Centrum
  • Municipality of Rotterdam
  • Vereniging Trustfonds Erasmus Universiteit Rotterdam
  • Ministerie van Onderwijs, Cultuur en Wetenschap
  • Erasmus Universiteit Rotterdam
  • Directorate-General XII, Science, Research, and Development

Zitieren

APA

Vom Hofe, I., Stricker, B. H., Ikram, M. K., Wolters, F. J., & Ikram, M. A. (2025). Long‐Term Exposure to Non‐Steroidal Anti‐Inflammatory Medication in Relation to Dementia Risk. Journal of the American Geriatrics Society, 73(5), 1484-1490. https://doi.org/10.1111/jgs.19411

Vancouver

Vom Hofe I, Stricker BH, Ikram MK, Wolters FJ, Ikram MA. Long‐Term Exposure to Non‐Steroidal Anti‐Inflammatory Medication in Relation to Dementia Risk. Journal of the American Geriatrics Society. 2025;73(5):1484-1490. doi:10.1111/jgs.19411

BibTeX
@article{VomHofe2025,
  author = {Vom Hofe, Ilse and Stricker, Bruno H and Ikram, M Kamran and Wolters, Frank J and Ikram, M Arfan},
  title = {Long‐Term Exposure to Non‐Steroidal Anti‐Inflammatory Medication in Relation to Dementia Risk},
  journal = {Journal of the American Geriatrics Society},
  year = {2025},
  volume = {73},
  number = {5},
  pages = {1484--1490},
  doi = {10.1111/jgs.19411}
}
Kostenlos starten →